1. Addressing Cardiovascular Events:

3. Educational Objectives

4. A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin monotherapy in high-risk patients presenting with acute coronary syndrome

5. Biologic Basis For Lowering LDL-C

6. LDL Hypothesis Is Lowering the LDL Enough, Or Does the Agent Matter?

7. Determinants of Atherosclerosis

9. Study Design

10. IMPROVE-IT Study Goals

11. IMPROVE-IT Not a Placebo Study

13. IMPROVE-IT Ezetimibe/Simvastatin Reduces Risk of Cardiovascular Events

14. IMPROVE-IT Safety Data

15. Safety of Other LDL Lowering Treatments

16. Abstract Presented at ACC 2015

17. Hypothesis

18. Number of Primary End Point Events

19. Total Primary End Point Events

20. What we know about “Lower is Better”

21. Conclusions

22. Conclusions

23. Abbreviations

24. Abbreviations (cont)

25. References

26. References (cont)

27. References (cont)